Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Avandia
|
| gptkbp:chemicalFormula |
C18H19N3O3S
sulfonamide thiazolidinedione_ring |
| gptkbp:class |
thiazolidinedione
|
| gptkbp:clinicalTrials |
combination therapy
Phase III monotherapy |
| gptkbp:compatibleWith |
99%
|
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:contraindication |
anemia
heart failure hypoglycemia bone fractures active liver disease |
| gptkbp:deployedTo |
2010
|
| gptkbp:dosageForm |
4 mg daily
8 mg daily |
| gptkbp:drugInterdiction |
distribution
glucose metabolism absorption elimination insulin sensitivity |
| gptkbp:endOfLife |
3 to 4 hours
|
| gptkbp:formulation |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rosiglitazone
|
| gptkbp:interactsWith |
insulin
other antidiabetic agents |
| gptkbp:isATypeOf |
122320-73-4
|
| gptkbp:marketedAs |
gptkb:GlaxoSmithKline
1999 |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
A10BG01
|
| gptkbp:patentExpiration |
2012
|
| gptkbp:provides |
gptkb:ADA
EASD |
| gptkbp:researchAndDevelopment |
controversial safety profile
efficacy in glycemic control impact on cardiovascular events |
| gptkbp:researchFocus |
metabolic syndrome
diabetes management cardiovascular risk |
| gptkbp:sideEffect |
heart failure
weight gain edema |
| gptkbp:triggerType |
PPAR-gamma agonist
|
| gptkbp:usedFor |
type 2 diabetes
|
| gptkbp:waterManagement |
urine
|